Senior Director, Global Commercial Development

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

Reporting to the Executive Director, Global Commercial Development – Pancreatic Cancer, this role will lead global commercial strategy and lifecycle development for the pancreatic cancer portfolio. This job description is across numerous positions, including daraxonrasib and zoldonrasib and future pipeline candidates, supporting opportunities in first-line metastatic, locally advanced, perioperative, and adjuvant disease, as well as future indications. This leader will translate evolving clinical evidence, patient and biomarker insights, and competitive dynamics into integrated global commercial strategies, portfolio investment recommendations, and stage-appropriate launch readiness. The role requires strong cross-functional leadership and close alignment with existing asset and indication teams.

Specifically, you will be responsible for:

- Own integrated pancreatic portfolio strategy: Lead global commercial development across therapeutic and pancreatic cancer settings; connect indication strategies to overall portfolio value.

- Guide indication and lifecycle prioritization: Evaluate clinical and commercial opportunities, unmet need, competitive differentiation, treatment sequencing, and investment trade-offs; present clear recommendations for development and governance decisions.

- Build treatment-setting strategies: Develop differentiated commercial hypotheses for first-line treatment, locally advanced disease, surgical/perioperative pathways, and adjuvant therapy, recognizing distinct patient journeys, customers, and evidence requirements.

- Integrate asset and combination positioning: Partner with relevant product teams to shape complementary daraxonrasib and zoldonrasib strategies, including biomarker-defined populations, potential combination approaches, and implications of future portfolio evolution.

- Lead patient and market forecasting: Develop global epidemiology, treatment-flow and patient-segmentation models, revenue scenarios, sensitivity analyses, and commercial value assessments across the continuum of pancreatic cancer care.

- Shape clinical development through a commercial lens: Collaborate with Clinical Development, Medical Affairs, HEOR, and Market Access on target populations, meaningful endpoints, duration of therapy, standards of care, and evidence needed for future adoption.

- Advance biomarker and patient-identification strategy: Work with Precision Medicine and Diagnostics on RAS/KRAS testing, KRAS G12D-defined populations, laboratory and referral workflows, accessibility, and the commercial implications of molecularly guided care.

- Connect the multidisciplinary ecosystem: Build a unified commercial understanding of oncologists, pancreatic surgeons, gastroenterologists, radiologists, pathologists, multidisciplinary tumor boards, academic centers, and community settings, in partnership with Medical Affairs and existing engagement teams.

- Align with cross-portfolio leaders: Coordinate with established first-line/metastatic teams, regional affiliates, and global brand teams to share insights and ensure best in class launches.

- Prepare for future launches and expansions: